From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

A sensor for liquid biopsy, its method of making, and its method of non-invasive use. The sensor includes a substrate with a surface functionalized with biotinylated antibodies. The biotinylated antibodies are arranged to engage with surface proteins on exosomes associated with malignant cancer cells such as glioma cells.

The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.

The present disclosure relates to Fibroblast Activating Protein(FAP) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing Fibroblast Activating Protein(FAP). The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Aspects of the present invention relate to a method of assessing disease in a subject comprising identifying at least one cellular phenotype characteristic of one or more cells in a sample of the subject, identifying at least one clinical characteristic of the subject, using the at least one cellular phenotype characteristic and the at least one clinical characteristic to assess a presence of oral lichenoid conditions (OLC) in the subject. In some embodiments, the OLC is oral lichen planus (OLP) and oral lichenoid lesions (OLL). In some embodiments, the at least one clinical characteristic is selected from the group consisting of: lesion involvement, lesion appearance, lesion area, lesion color and lesion location.

CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

The present invention relates to antibodies against the endothelin receptor subtype A, in particular monoclonal antibodies, fragments or derivatives thereof. The present invention also relates to the therapeutic or diagnostic use of this antibody or as a research tool in the field of cancers, in particular glioblastoma.

The present invention concerns the field of monoclonal antibodies, and describes an isolated anti-EPO antibody which binds human Erythropoietin (EPO) preventing its binding to specific receptors and inhibiting their signaling pathway. The invention further describes a polynucleotide encoding the anti-EPO antibody, a vector comprising the polynucleotide and a host cell comprising the vector. Furthermore, a method is described, for producing the antibody. The compounds of the invention, alone or in combination, are effective in the treatment of proliferative disorders such as cancers, where they cause the induction of apoptosis and overcome drug-resistance in cancer cells, cancer stem cells and in tumor endothelial cells, of autoimmune and non-autoimmune based chronic inflammatory diseases, in the treatment of patients undergoing organ or tissue transplant, in the treatment of haemophilic arthropathy, neurodegenerative diseases and neurological diseases in which neuro inflammation plays a role in pathogenesis, for example: multiple sclerosis, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, autoimmune disease with neurologic involvement, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases, ophthalmic pathologies such as neovascular age related (NVAMD), macular degeneration, retinal vein occlusion (RVO), metabolic syndromes, diabetes, and neuropathic pain disorders and the invention described compositions comprising them and medical uses of the composition. In a further aspect, the invention discloses the antibody, composition, or immunoconjugate for use as a medicament.

In alternative embodiments, provided are immunohistochemistry (IHC) methods for determining and scoring reproducibly the extent of nuclear expression of protein Ki-67 (also known as MK167) in a tissue sample. In alternative embodiments, provided are methods for diagnosing, treating or ameliorating or assessing the risk of recurrence for a cancer or a tumor using an IHC method as provided herein. In alternative embodiments, provided are kits comprising components and instructions for practicing methods as provided herein.